125 related articles for article (PubMed ID: 22587632)
21. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
22. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer.
Lo YW; Lin ST; Chang SJ; Chan CH; Lyu KW; Chang JF; May EW; Lin DY; Chou HC; Chan HL
J Cell Mol Med; 2015 Apr; 19(4):744-59. PubMed ID: 25639359
[TBL] [Abstract][Full Text] [Related]
24. Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.
Bober P; Alexovic M; Talian I; Tomkova Z; Viscorova Z; Benckova M; Andrasina I; Ciccocioppo R; Petrovic D; Adamek M; Kruzliak P; Sabo J
J Cancer Res Clin Oncol; 2017 Jan; 143(1):35-42. PubMed ID: 27620743
[TBL] [Abstract][Full Text] [Related]
25. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
Lauricella M; Ciraolo A; Carlisi D; Vento R; Tesoriere G
Biochimie; 2012 Feb; 94(2):287-99. PubMed ID: 21835222
[TBL] [Abstract][Full Text] [Related]
26. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
27. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.
Jeon YJ; Khelifa S; Ratnikov B; Scott DA; Feng Y; Parisi F; Ruller C; Lau E; Kim H; Brill LM; Jiang T; Rimm DL; Cardiff RD; Mills GB; Smith JW; Osterman AL; Kluger Y; Ronai ZA
Cancer Cell; 2015 Mar; 27(3):354-69. PubMed ID: 25759021
[TBL] [Abstract][Full Text] [Related]
28. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis.
Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A
Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037
[TBL] [Abstract][Full Text] [Related]
29. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS
PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619
[TBL] [Abstract][Full Text] [Related]
30. Identification of plant extracts sensitizing breast cancer cells to TRAIL.
Abdelhamed S; Yokoyama S; Hafiyani L; Kalauni SK; Hayakawa Y; Awale S; Saiki I
Oncol Rep; 2013 May; 29(5):1991-8. PubMed ID: 23426404
[TBL] [Abstract][Full Text] [Related]
31. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.
Oh B; Park S; Pak JH; Kim I
Biochem Biophys Res Commun; 2012 May; 422(1):42-7. PubMed ID: 22554523
[TBL] [Abstract][Full Text] [Related]
33. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Oncol Rep; 2003; 10(6):1925-30. PubMed ID: 14534720
[TBL] [Abstract][Full Text] [Related]
34. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.
Xu J; Zhou JY; Tainsky MA; Wu GS
Cancer Res; 2007 Feb; 67(3):1203-11. PubMed ID: 17283156
[TBL] [Abstract][Full Text] [Related]
35. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
36. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
37. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD
J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527
[TBL] [Abstract][Full Text] [Related]
38. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
39. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
